Release date: 2015-10-22 On October 16, Shanghai Tianshili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tasly Pharmaceutical Group, signed the “Sino-foreign Joint Venture Contract†and “Intellectual Property Transfer and License Agreement†with CBCSPVIILIMITED and South Korea’s Genexine. Founded in 1999, Genexine is based in proprietary hyFc technology and immunotherapeutic technology. Genexine was launched in Korea in 2009. The purpose of this cooperation is to introduce Genexine's various long-acting protein drugs, and jointly invest in the establishment of the joint venture company Tianshizhen Biotechnology (Tianjin) Co., Ltd., and cooperate in the research and development of new drugs in China. It is reported that the transaction involves two aspects: three Chinese rights to enter clinical research or upcoming clinical research products, including GX-H9 (long-acting human growth hormone), GX-G6 (long-acting GLP-1) and GX-G3 (Long-acting G-CSF); global rights to two preclinical research products, including GX-P2 (long-acting PD-L1) and GX-G8 (long-acting GLP-2). Tasly said that the transaction and product introduction are in line with the strategic layout of Tasly's “one center with two wings†in the bio-pharmaceutical field, which will greatly enrich Tasly's product line in the bio-pharmaceutical field. In fact, this is the second protein drug cooperation project announced by Tasly in the near future. At the end of August this year, Tasly Pharmaceutical Group signed a cooperation agreement with Zhuhai Yisheng Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as “Yisheng Biologicalâ€) to jointly develop and operate recombinant protein drugs, including research and development, clinical trials, manufacturing and marketing; The term of cooperation is 10 years from the date of signing the agreement. It is reported that Yisheng Bio was established in 1996 and is a wholly-owned subsidiary of Yisheng Biotechnology Co., Ltd., a listed company on the main board of the Hong Kong Stock Exchange. It is committed to the use of genetic engineering technology to develop, produce and sell wound repairs with independent intellectual property rights. Biopharmaceuticals, successfully developed three national class I genetic engineering new drugs. Source: Bio-Exploration Garden Supply Store,Indoor Gardening Supplies,Landscape Supplies,Magic Garden Supplies Changzhou Satidi Import and Export Co., Ltd. , https://www.czguanjiechuck.com